anticoagulant

(redirected from anticoagulant agent)
Also found in: Thesaurus, Medical, Encyclopedia.

an·ti·co·ag·u·lant

 (ăn′tē-kō-ăg′yə-lənt, ăn′tī-)
n.
A substance that slows or prevents the clotting of blood.
adj.
Acting as an anticoagulant.

an′ti·co·ag′u·la′tive (-lā′tĭv, -lə-tĭv) adj.

anticoagulant

(ˌæntɪkəʊˈæɡjʊlənt)
adj
(Medicine) acting to prevent or impair coagulation, esp of blood
n
(Pharmacology) an agent that prevents or impairs coagulation

an•ti•co•ag•u•lant

(ˌæn ti koʊˈæg yə lənt, ˌæn taɪ-)

adj.
1. Also, an•ti•co•ag•u•la•tive (-ˌleɪ tɪv, -lə tɪv) preventing coagulation, esp. of blood.
n.
2. an anticoagulant agent, as heparin.
[1900–05]

anticoagulant

A drug used to decrease the clotting ability of the blood, especially after heart surgery.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.anticoagulant - medicine that prevents or retards the clotting of bloodanticoagulant - medicine that prevents or retards the clotting of blood
dicoumarol, dicumarol - an anticoagulant drug that has now been largely replaced by warfarin
heparin, Lipo-Hepin, Liquaemin - a polysaccharide produced in basophils (especially in the lung and liver) and that inhibits the activity of thrombin in coagulation of the blood; it (trade names Lipo-Hepin and Liquaemin) is used as an anticoagulant in the treatment of thrombosis and in heart surgery
medicament, medication, medicinal drug, medicine - (medicine) something that treats or prevents or alleviates the symptoms of disease
Coumadin, warfarin - an anticoagulant (trade name Coumadin) use to prevent and treat a thrombus or embolus
Translations
antikoagulantti

anticoagulant

[ˈæntɪkəʊˈægjʊlənt]
A. ADJanticoagulante
B. Nanticoagulante m

anticoagulant

[ˌæntɪkəʊˈægjʊlnt] adj & nanticoagulante (m)

an·ti·co·ag·u·lant

n. anticoagulante, medicamento usado para evitar coágulos.

anticoagulant

adj & n anticoagulante m; lupus — anticoagulante lúpico
References in periodicals archive ?
All blood samples were collected in tubes with EDTA (potassium ethylenediaminetetraacetate) which served as the anticoagulant agent.
When the fatty material bursts, a clot can form unless an anticoagulant agent is being taken to reduce the risk of platelet aggregation.
6 January 2010 - US biopharmaceutical company ARYx Therapeutics Inc (NASDAQ: ARYX) said yesterday it has received guidance in writing from the US Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of its anticoagulant agent, tecarfarin (ATI-5923).
A direct association between MPV and platelet activation is not easy to establish; because, the reliability of the results in the previously studies depend on the preanalytical factors; such as the time between sampling and analyzing, the anticoagulant agent in the tube.
Inc he led development programs of novel therapies for dislipidemic patients (Tredaptive[R] the Nicotinic acid/laropripant combination and Vytorin[R]/Inegy[R] the Ezetimibe/Simvastatin combination tablet), and at Bayer Healthcare Pharmaceuticals, he led the clinical development program for a novel anticoagulant agent for patients with atrial fibrillation (Xarelto,[R] the direct factor Xa inhibitor, rivaroxaban).
ARYx currently has four products in clinical development: a prokinetic agent for the treatment of various gastrointestinal disorders, naronapride (ATI-7505); an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242.
ARYx currently has four products in clinical development: an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242.
ARYx announced earlier this year that it had received guidance from the FDA that only one additional clinical trial is required for the filing of an NDA for its anticoagulant agent tecarfarin, should the safety and efficacy data from that trial support tecarfarin's approval.
ARYx currently has four products in clinical development: an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242.

Full browser ?